Frontiers in Cardiovascular Medicine最新文献

{"title":"Case Report: Minimally invasive management of suspected active bleeding from intercostal vessel after axillary thoracotomy ventricular septal defect repair: an application of Foley catheter.","authors":"Yunfei Tian, Erjia Huang, Mengdi Zhang, Jinzhe Fan, Wei Li, XiaoHui Yang, Wei Su, Xicheng Deng","doi":"10.3389/fcvm.2025.1511221","DOIUrl":"10.3389/fcvm.2025.1511221","url":null,"abstract":"<p><p>The right axillary thoracotomy, an alternative approach for selected open-heart procedures, offers aesthetic advantages. However, intercostal vessel injury is a potential postoperative complication that can lead to major bleeding. Herein, we report a case of postoperative active bleeding from intercostal vessel injury after right axillary thoracotomy for ventricular septal defect repair. Hemorrhage was successfully halted by compressing the suspected bleeding site with a Foley catheter inserted through the chest wall. This case demonstrates a simple management method of active intercostal vascular bleeding after cardiac operation. It may be an appropriate option in selected postoperative patients with a high index of suspicion of intercostal vascular bleeding after operation via a thoracotomy approach.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1511221"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Case Report: Endovascular therapy for an iatrogenic vertebrojugular arteriovenous fistula and pseudoaneurysm induced by multiple vascular procedures.","authors":"","doi":"10.3389/fcvm.2025.1628458","DOIUrl":"https://doi.org/10.3389/fcvm.2025.1628458","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.3389/fcvm.2025.1493342.].</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1628458"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of psychological intervention-assisted cardiac rehabilitation on kinesiophobia in individuals diagnosed with coronary heart disease.","authors":"Xiaoping Guo, Wei Li, Jing Sun, Yanzhuo Ma","doi":"10.3389/fcvm.2025.1561505","DOIUrl":"10.3389/fcvm.2025.1561505","url":null,"abstract":"<p><strong>Objective: </strong>Kinesiophobia is prevalent among patients with coronary heart disease (CHD). This study aimed to explore whether psychologically-informed cardiac rehabilitation (CR) could positively influence the reduction of kinesiophobia in CHD patients.</p><p><strong>Methods: </strong>A total of 86 CHD patients, who sought treatment at Bethune International Peace Hospital between June 2022 and June 2023, were selected and divided into two groups: a psychological intervention group comprising 42 patients and a conventional CR group of 44 patients. The conventional CR group received standard CR intervention, whereas the psychological intervention group underwent CR intervention augmented with psychological support. The effectiveness of these interventions was evaluated using the Self-Rating Depression Scale (SDS), the Self-Rating Anxiety Scale (SAS), the Multidimensional Exercise Self-Efficacy Scale (MSES), the TSK-Heart (for assessing kinesiophobia in cardiac patients), and the Short Form Health Survey (SF-36) scores.</p><p><strong>Results: </strong>Following the intervention, the SDS and SAS scores of the psychological intervention group were higher than those of the conventional CR group. The MSES dimension scores and the total score of the psychological intervention group were elevated in comparison to the CR group. Conversely, the TSK-Heart dimension scores and the total score of the psychological intervention group were diminished relative to the CR group. Additionally, the SF-36 dimension scores and total score of the psychological intervention group surpassed those of the CR group post-intervention.</p><p><strong>Conclusion: </strong>The integration of psychologically-supported CR into the rehabilitation regimen for CHD patients effectively mitigates negative emotions, enhances self-efficacy, and markedly reduces kinesiophobia, thus significantly improving overall quality of life.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1561505"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149134/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advances in pathophysiological mechanisms and therapeutic efficacy of exercise rehabilitation in patients with heart failure with preserved ejection fraction.","authors":"Juanjuan Fang, Zhenhua Wang, Jiangshui Yu","doi":"10.3389/fcvm.2025.1598878","DOIUrl":"10.3389/fcvm.2025.1598878","url":null,"abstract":"<p><p>Heart Failure with Preserved Ejection Fraction (HFpEF) is a heterogeneous syndrome characterized by systemic multiorgan dysfunction, and exercise rehabilitation has emerged as a promising non-pharmacological intervention. This review synthesizes current evidence on the pathophysiological mechanisms underlying exercise intolerance in HFpEF and evaluates the therapeutic efficacy of exercise-based interventions. Key mechanisms include myocardial stiffness due to chronic inflammation, coronary microvascular dysfunction, skeletal muscle mitochondrial impairment, and endothelial dysfunction. Clinical studies indicate that tailored exercise regimens (e.g., combined aerobic-resistance training) improve peak oxygen consumption, 6 min walking distance, and quality of life through multi-organ adaptations: enhanced cardiac output reserve, skeletal muscle metabolic remodeling, and reduced systemic inflammation. However, challenges persist in optimizing exercise prescriptions for phenotypically diverse HFpEF subpopulations (e.g., obese, elderly frail). Future research must prioritize phenotype-specific protocols, validate long-term outcomes (mortality, hospitalization), and integrate biomarkers (e.g., H₂FPEF score) with digital health technologies to advance precision rehabilitation strategies. This review highlights the imperative for mechanistic insights to guide clinical translation in HFpEF management.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1598878"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148885/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: An innovative approach to coronary artery perforation in chronic total occlusion using autologous flaps.","authors":"Chen Genrui, Wang Huan, Chen Youhu, Li Chengxiang, Gao Haokao","doi":"10.3389/fcvm.2025.1594967","DOIUrl":"10.3389/fcvm.2025.1594967","url":null,"abstract":"<p><strong>Background: </strong>A percutaneous coronary intervention (PCI) for chronic total occlusion (CTO) carries a significant risk of coronary artery perforation (CAP). The typical treatment for proximal large CAP often requires the deployment of covered stents. However, this becomes impractical in situations where the antegrade wire has not successfully crossed the CTO lesion. In addition, emergency coronary artery bypass grafting for perforation after CTO-PCI is associated with a high in-hospital mortality rate.</p><p><strong>Case report: </strong>A patient presented with a left anterior descending artery (LAD) CTO involving the large first diagonal (D1) branch within the CTO segment. The D1 vessel was recanalized successfully using an antegrade approach. Before several attempts, the LAD CTO could n't be crossed, and an Ellis type Ⅲ perforation was visualized in the mid-LAD segment after bifurcation of the D1 vessel, which was created using a knuckled wire supported with a Corsair microcatheter. Subsequently, the perforation was effectively controlled by a tamponade balloon deployed from the D1 vessel to the proximal LAD. Before the retrograde wire crossed the LAD CTO, the dissection and re-entry techniques (DARTs) were used to recanalize the CTO lesion, intentionally creating subintimal dissection flaps. These autologous dissection flaps, together with drug-eluting stents instead of covered stents, successfully sealed the perforation.</p><p><strong>Conclusion: </strong>The innovative approach of using autologous dissection flaps created with DART in CTO-PCI to seal perforations is clinically feasible and effective.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1594967"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Practical approach to unmask unspecific adverse effects under lipid-lowering medication.","authors":"Thomas Büttner, Gunther Hartmann, Martin Coenen","doi":"10.3389/fcvm.2025.1604129","DOIUrl":"10.3389/fcvm.2025.1604129","url":null,"abstract":"<p><p>The nocebo effect, driven by negative expectations rather than pharmacological mechanisms, contributes significantly to medication non-adherence, particularly in lipid-lowering therapy. Up to 50% of reported statin-related adverse effects may result from nocebo responses, leading to unnecessary discontinuation and increased cardiovascular risk. Blinded provocation tests may offer a solution for the differentiation of true drug intolerance from nocebo-driven symptoms. Although this methodology is well-established in experimental studies, it has not been transferred to routine clinical practice so far. We present a 65-year-old female with hypercholesterolemia and cardiovascular risk factors who experienced recurrent, dose-dependent left-sided lower abdominal pain with different lipid-lowering drugs. These symptoms prompted repeated and ultimately continuous treatment discontinuations, each followed by resolution of complaints. Despite extensive evaluations, no organic cause was found. To assess the role of nocebo effects, a six-week single-blinded, placebo-controlled crossover provocation test with a commercially available placebo preparation and atorvastatin placed in neutral pill containers was conducted. Upon initiation of the provocation phase, the patient experienced similar intermittent symptoms under both treatments. The pain ratings on a numeric rating scale did not significantly differ during placebo (mean: 2.75) and atorvastatin administration (mean: 3.26), suggesting that these symptoms were not pharmacologically induced. Following information of the patient, atorvastatin therapy could be continued. During continued intake over several weeks, symptoms further diminished, reinforcing the therapeutic value of addressing nocebo effects. This case report provides for the first time the structured and detailed step-by-step description of a pragmatic approach for a prospective blinded, placebo-controlled provocation testing that can directly be implemented in routine clinical practice. This method enables the distinction of true drug intolerance from nocebo effects, thereby enabling necessary therapies and highlighting its diagnostic and therapeutic potential.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1604129"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and safety of rivaroxaban in patients with atrial fibrillation and heart failure in clinical practice: an indirect comparison of national and international registries.","authors":"Jose Maria Cepeda, Nicolas Manito, Alejandro Recio Mayoral, Iñaki Lekuona, Miguel Castillo Orive, Elvira Blanco Labrador, María Teresa Blasco, Nuria Farré, José Manuel García Pinilla, Javier Jiménez-Candil, Carles Rafols, Juan Jose Gomez Doblas","doi":"10.3389/fcvm.2025.1451499","DOIUrl":"10.3389/fcvm.2025.1451499","url":null,"abstract":"<p><strong>Background: </strong>The objective of the study was to analyze and compare the effectiveness and safety of rivaroxaban in patients with atrial fibrillation (AF) and heart failure (HF).</p><p><strong>Methods: </strong>The clinical profile and outcomes of the FARAONIC study were indirectly compared with those of the ROCKET-AF trial and other national and international observational registries.</p><p><strong>Results: </strong>In FARAONIC, the median age was 73.7 years, 34.1% were women, and the median CHA₂DS₂-VASc was 4.1. In the rivaroxaban arm of ROCKET-AF in patients with HF, these statistics were 72 years, 39.1%, and 5.1, respectively. In the national/international registries of patients with HF receiving rivaroxaban, these statistics were 74.0-75.3 years, 40.8%-41.4%, and 3.2-4.5, respectively. In the GLORIA-AF (dabigatran) and ETNA-AF (edoxaban) trials, these numbers were 69.9-75.3 years, 39.3%-41.6%, and 3.8-4.4, respectively. Among the HF populations, annualized rates of stroke or systemic embolism were 0.75% in FARAONIC (vs. 1.90% in ROCKET-AF, 0.92%-1.2% in national/international registries with rivaroxaban, 0.82% in GLORIA-AF, and 0.88% in ETNA-AF). Rates of major bleeding in FARAONIC were 1.55% (vs. 1.4%-3.86% in the national/international registries with rivaroxaban, 1.20% in GLORIA-AF, and 1.65% in ETNA-AF).</p><p><strong>Conclusion: </strong>In clinical practice, AF patients with HF, anticoagulated with rivaroxaban are old, have many comorbidities and have a high thromboembolic risk. Despite this, rates of adverse events are low.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1451499"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12150239/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil <i>Myo5c</i> gene downregulation is associated with postoperative organ dysfunction following pediatric cardiac surgery with cardiopulmonary bypass.","authors":"Wiriya Maisat, Sumiti Sandhu, Samuel Kim, Hanna Van Pelt, Sek Won Kong, Juan Ibla, Koichi Yuki","doi":"10.3389/fcvm.2025.1380606","DOIUrl":"10.3389/fcvm.2025.1380606","url":null,"abstract":"<p><strong>Introduction: </strong>Pediatric cardiac surgery with cardiopulmonary bypass (CPB) carries substantial risks of postoperative organ dysfunction and mortality, making the identification of biomarkers for postoperative organ dysfunction crucial for enhancing patient outcomes. As neutrophils play a major role in the perioperative setting and act as double-edge swords to the host, we examined neutrophil transcriptomic profiles in pediatric patients undergoing cardiac surgery with CPB.</p><p><strong>Methods: </strong>We enrolled into this study from May 31, 2022, to February 22, 2023.</p><p><strong>Results: </strong>32% developed postoperative complications, mainly in the respiratory and cardiovascular systems. Patients in the complication group showed higher PELOD-2 scores on postoperative day 2. These patients experienced longer duration of mechanical ventilation and extended ICU and hospital stays. RNA sequencing of neutrophils revealed significant changes in gene expression after CPB, with the <i>myo5c</i> gene emerging as a key downregulated transcript. Its expression was inversely correlated with PELOD-2 score, IL-6 levels, and markers of neutrophil and platelet activation. Furthermore, <i>myo5c</i>-knockout HL60 cells exhibited enhanced neutrophil extracellular traps (NETs) formation upon stimulation, supporting a potential regulatory role for <i>myo5c</i> in neutrophil activation and systemic inflammation.</p><p><strong>Discussion: </strong>While <i>myo5c</i> was not an independent predictor of complications, its expression was consistently associated with clinical severity, suggesting it may serve as a useful biomarker for early risk stratification of postoperative complications in this vulnerable pediatric population.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1380606"},"PeriodicalIF":2.8,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148857/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144265748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A diagnostic prediction model for cardiovascular diseases (CVDs) in patients with psoriasis.","authors":"Xiao-Yang Guo, Guo-Hua Xue, Yue-Min Zou, Jia-Qi Chen, Shi Chen, Dong-Mei Zhou","doi":"10.3389/fcvm.2025.1584305","DOIUrl":"10.3389/fcvm.2025.1584305","url":null,"abstract":"<p><strong>Objective: </strong>Individuals with psoriasis are related to a significantly increased risk of cardiovascular diseases (CVDs), the major cause of death among psoriasis patients. Prompt diagnosis and intervention of CVDs can effectively retard the progression of the disease. This study developed and validated the CVDs diagnostic prediction model for psoriasis patients.</p><p><strong>Methods: </strong>Medical records from psoriasis patients admitted to Beijing Hospital of Traditional Chinese Medicine between January 2009 and September 2024 were reviewed retrospectively. Patients were randomized as training and validation sets at the 7:3 ratio. We then selected variables through univariate logistic regression and least absolute shrinkage and selection operator (LASSO). The screened factors were subsequently incorporated in a multivariate logistic regression model for establishing the diagnostic nomogram. Moreover, this constructed model was validated internally and externally, and its performance was compared with a previous model.</p><p><strong>Results: </strong>In this study, altogether 2,685 psoriasis patients were included. Five variables were finally selected for nomogram construction, which were age, hypertension, diabetes, dyslipidemia, and fasting blood glucose (FBG). According to our results, this model achieved favorable discrimination ability, and the area under the curve (AUC) values after 500 bootstrap resampling was 0.9355 (95% CI, 0.9219-0.9491) and 0.9118 (95% CI, 0.8899-0.9338) for training and validation sets, separately. Besides, calibration curves closely matched predicted and real values for both sets. Further, as indicated by DCA results, this model showed a high net benefit at predicted probabilities below 79% and 80% of training and validation sets, separately. In total, 188 psoriasis patients were enrolled in this work, with NHANES publicly available data being utilized for external validation. The corrected AUC was 0.8293 (95% CI, 0.7574-0.9012), and the calibration and DCA curves demonstrated good accuracy and clinical utility. Additionally, the model showed an increased AUC compared with a previously published diagnostic model. Its net reclassification index (NRI) and discrimination improvement index (IDI) were positive, showing that our model was superior to the previous model.</p><p><strong>Conclusion: </strong>This study provides a cost-effective and practical tool that can assist physicians in identifying psoriasis patients at a higher CVDs risk. This may facilitate early disease diagnosis and intervention.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1584305"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The gut-heart axis: unveiling the roles of gut microbiota in cardiovascular diseases.","authors":"Yuan Zhang, Huimin Wu, Mu Jin, Guirong Feng, Sheng Wang","doi":"10.3389/fcvm.2025.1572948","DOIUrl":"10.3389/fcvm.2025.1572948","url":null,"abstract":"<p><p>The gut microbiome refers to the collective genomes of the approximately 1,000-1,150 microbial species found in the human gut, called the gut microbiota. Changing the gut microbiota composition has been shown to affect cardiovascular health significantly. Numerous studies have demonstrated the part that gut microbiota and its metabolites play in the development and course of several illnesses, including colon cancer, heart failure, stroke, hypertension, and inflammatory bowel disease. With cardiovascular diseases responsible for more than 31% of all fatalities globally, conditions like hypertension, atherosclerosis, and heart failure are serious global health issues. Developing preventive measures to fight cardiovascular diseases requires understanding how the gut microbiota interacts with the cardiovascular system. Understanding the distinctive gut microbiota linked to cardiovascular diseases has been made possible by microbial sequencing analysis. The gut microbiota and cardiovascular diseases are closely related, and more profound knowledge of this association may result in treatment strategies and broad guidelines for enhancing cardiovascular health through gut microbiome modification. This review summarizes the role of gut microbiota in cardiovascular diseases, highlighting their influence on disease progression and potential therapeutic implications.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1572948"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}